Company intelligence / Profile preview
Tyme Technologies
Bedminster, New Jersey, United Statestymeinc.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Tyme Technologies’ lead candidate SM‑88 showed early clinical activity and low toxicity in multiple advanced cancers. The company discontinued its Phase 2/3 trial of SM‑88 in January 2022 before being acquired by Syros Pharmaceuticals. Other pipeline assets remained preclinical at the time of acquisition[6][9].
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Small moleculeSynthetic bile acid (for TYME-19)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Mayo Clinic and Georgetown University for biomarker/mechanism studiesEvotec for global drug development support
Beyond the preview
Go deeper on Tyme Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyme Technologies.